SCHEMBL20969726

SCHEMBL20969726

COc1ccc(CCN(Cc2ccc(C(=O)O)cc2)c2nc3cc(C(F)(F)F)ccc3s2)cc1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KARS1 Q15046 1/20 0.62
PPARD Q03181 8/20 0.54
PPARG P37231 2/20 0.54
PPARA Q07869 1/20 0.54
CSNK1D P48730 1/20 0.44
LPAR1 Q92633 1/20 0.43
LPAR5 Q9H1C0 1/20 0.43
CACNA1H O95180 1/20 0.43
CACNA1B Q00975 1/20 0.43
TAS2R14 Q9NYV8 1/20 0.42
MAPT P10636 1/20 0.42
SUV39H1 O43463 1/20 0.42
EHMT2 Q96KQ7 1/20 0.42
PRMT1 Q99873 1/20 0.42
SLC2A1 P11166 1/20 0.41
KDM4E B2RXH2 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20969704 0.93 KARS1 (0.62) KARS1PPARDPPARGPPARACSNK1D
SCHEMBL31011481 0.88 PPARD (0.53) KARS1PPARDPPARGPPARACSNK1D
SCHEMBL20969643 0.87 KARS1 (0.66) KARS1PPARDPPARGPPARALPAR1
SCHEMBL20969678 0.86 KARS1 (0.65) KARS1PPARDPPARGPPARALPAR1
SCHEMBL20969558 0.86 KARS1 (0.65) KARS1PPARDPPARGPPARALPAR1
SCHEMBL20969732 0.85 KARS1 (0.66) KARS1PPARDPPARGPPARALPAR1
SCHEMBL20969604 0.85 KARS1 (0.44) KARS1PPARDPPARGPPARACSNK1D
SCHEMBL20969655 0.84 KARS1 (0.69) KARS1PPARDPPARGPPARALPAR1
SCHEMBL20969651 0.83 KARS1 (0.65) KARS1PPARDPPARGPPARALPAR1
SCHEMBL20969654 0.82 KARS1 (0.66) KARS1PPARDPPARGPPARALPAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3483149-B1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME YUHAN CORP (KR) 2021-01-13 EP claimed
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same YUHAN CORPORATION (KR) 2019-08-20 US claimed
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same YUHAN CORPORATION (KR) 2019-05-16 US claimed
EP-3483149-A1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Yuhan Corporation (KR) 2019-05-15 EP claimed
EP-3483149-B1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME YUHAN CORP (KR) 2021-01-13 EP disclosed
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same YUHAN CORPORATION (KR) 2019-08-20 US disclosed
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same YUHAN CORPORATION (KR) 2019-05-16 US disclosed
EP-3483149-A1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Yuhan Corporation (KR) 2019-05-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same ILK, SBDS, BDKRB1 KARS1 6/4885PPARD 30/4885PPARG 238/4885
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same ILK, SBDS, BDKRB1 KARS1 6/4885PPARD 30/4885PPARG 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.